ROBERT J. MISBIN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In his recent review of hormonal therapy for metastatic breast cancer, Dr. Korenman (1) did not include a relatively new but promising alternative to surgical adrenalectomy, blockade of adrenocortical synthesis by aminoglutethimide. Santen, Lipton, and Kendall (2) have reported that eight of 22 patients (36%) with metastatic breast cancer had objective remission lasting from 3 to more than 19 months when treated with aminoglutethimide and glucocorticoid replacement. Three additional patients (14%) experienced a subjective relief of symptoms. In a series of 65 patients reported by Gale and associates (3), 21 (33%) had objective remission lasting from 3
MISBIN RJ. Aminoglutethimide for Metastatic Breast Cancer. Ann Intern Med. ;86:828–829. doi: 10.7326/0003-4819-86-6-828
Download citation file:
Published: Ann Intern Med. 1977;86(6):828-829.
Breast Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use